
Michael Byung-ju Kim: Raider or rescuer?
Michael Byung-ju Kim, founder of private equity firm MBK Partners, who was once hailed as the "godfather of Asian private equity" for landmark deals with his namesake firm, now faces accusations of being a corporate raider, amid mounting criticism of his aggressive tactics.
In 2015, he made global headlines with the acquisition of Korean supermarket chain Homeplus for 7.2 trillion won ($4.92 billion) — the largest private equity-led deal in Asiaat the time.
A decade later, that very deal has come back to haunt him. In 2025, Homeplus' debt woes have forced Kim to pledge his own assets to cover overdue payments, a bruising turn for the industry veteran who built his fortune on bold, successful buyouts.
'While private equity firms expect both gains and losses, Kim's pledge signals MBK's acknowledgment of failure in its Homeplus strategy," Lee Jeong-hwan, an associate professor at Hanyang University's College of Economics and Finance.
Kim began his finance career at Goldman Sachs in 1986 before moving to Salomon Smith Barney, where he served as regional managing director, leading investments in Asia. In 1999, he joined Carlyle, becoming Asia president and driving the private equity giant's regional expansion.
One landmark deal that brought Lee into the industry spotlight was Carlyle's 2000 acquisition of KorAm Bank, where Carlyle and JPMorgan jointly acquired a 36 percent stake for $430 million, later selling it to Citigroup for $2.7 billion in a successful exit.
Building on this success, Kim left Carlyle in 2005 to found MBK Partners, a private equity firm named after himself. In the same year Korea had introduced regulatory frameworks for private equity, with Kim playing a key role in shaping the sector's growth.
With MBK now the largest buyout firm in Northeast Asia, managing over $30 billion in assets, Kim is among Korea's wealthiest individuals. In 2024, Forbes ranked him as the country's second-richest man, with a net worth of $9.7 billion, following Samsung Chairman Lee Jae-yong.
Kim has long emphasized improving corporate governance as one of his investment goals, particularly within Korea's "chaebol" system.
In a 2024 interview with a Hong Kong news outlet, he described "corporate governance as a leading theme" in his Korean investments, citing the "structural hurdles" posed by family-run conglomerates. He also expressed his criticism of the system in a 2022 interview about his novel, "Offerings," where he said frustration with greed on Wall Street and corruption in Korea's chaebol inspired the book.
In line with this, MBK has cited governance improvement as its rationale for involvement in high-profile, controversial ownership disputes within Korean conglomerates.
In 2023, MBK partnered with a member of Hankook Tire & Technology's estranged founding family for a tender offer, but the bid failed due to insufficient shares. More recently, MBK has been in an ongoing ownership feud against Korea Zinc's Choi family, aligning with the zinc smelter's largest shareholder, Young Poong.
While such aggressive ownership moves are more common in Western markets, industry insiders argue they clash with Korea's investment culture.
"The private equity system was introduced to support (not challenge) local industry. That is why government policies and funds have backed it," a domestic private equity official said. "And challenging ownership structures without clear rationale carries significant risk."
Despite controversies over failed investments and ownership disputes, professor Lee doesn't view them as failures of MBK's strategy.
"While MBK may not have made the best investments, the lack of profitability in these companies is largely due to poor management, not MBK," he said. "There are always ups and downs — what matters is investor confidence."
The investment strategies employed by MBK could damage its standing in Korea's investment environment, where public perception impacts fund raising.
"In Korea, the largest investors are state pension funds managing public money," an official at a private equity firm said, noting that public reputation is a key factor these funds evaluate when reviewing partners. "While such aggressive strategies may be acceptable globally, decisions that severely damage its reputation are undesirable."
Indeed, the National Pension Service, Korea's largest public fund, has distanced itself from MBK and its controversies, disclosing that its latest investment in MBK was conditioned on the company not getting involved in hostile takeovers. The NPS is considering applying this rule to future contracts with private equity firms.
Further tarnishing MBK's reputation, the Korean-American entrepreneur faces personal controversies, including tax evasion allegations and concerns over funds being funneled abroad. The local tax agency, which reportedly imposed a 40 billion won tax liability on Kim in 2022, is now conducting a similar investigation.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Korea Herald
3 hours ago
- Korea Herald
Samsung chief visits Songdo to boost bio push
Samsung Electronics Chair Lee Jae-yong visited Samsung Biologics' campus in Songdo, Incheon, on Monday, a move interpreted by industry observers as an indication of his commitment to nurturing the bio sector as the group's next major growth engine following semiconductors. According to industry sources, the chair toured the Songdo campus of Samsung Biologics alongside key executives, including Samsung Electronics Vice Chair Jung Hyun-ho and Samsung Biologics CEO John Rim. During the visit, he reportedly inspected production facilities and process equipment and held strategic discussions with senior management. Since assuming leadership of Samsung, Lee has emphasized the importance of developing the bio business into a future growth pillar on par with semiconductors. In 2022, he attended the completion ceremony of Samsung Biologics' Plant 4 on the Songdo campus. Samsung Biologics surpassed 4 trillion won ($2.9 billion) in consolidated annual revenue last year, becoming the first Korean biopharma company to reach the milestone. In a strategic move to bolster competitiveness, the company announced on May 22 the spinoff of Samsung Bioepis into a newly established holding company, Samsung Epis Holdings. Under the reorganization, Samsung Biologics will continue focusing exclusively on its core CDMO operations. Samsung Epis Holdings will serve as an R&D-driven holding company responsible for biosimilar development, new technology investment and global strategy planning. By structurally separating its two growth pillars — CDMO and biosimilars — Samsung aims to build a more agile and responsive system that can better meet the demands of customers, investors and the broader market.


Korea Herald
3 hours ago
- Korea Herald
S. Korea-China-Japan cooperation crucial as ‘buffer' as Trump 2.0 roils Asia
APEC summit will serve as springboard for bolstering trilateral coordination, observers say Trilateral cooperation among South Korea, China and Japan has become more essential than ever as a buffer in Northeast Asia fraught with mounting volatility and uncertainty under US President Trump's second term, former high-ranking officials and experts said. Observers from the three countries held the view that Northeast Asia has become the central battleground in the intensifying great-power rivalry between the US and China during a forum hosted by the North-East Asia Research Foundation, a Seoul-based think tank, on Monday. Chung Duck-koo, former minister of trade, industry and energy, underscored that 'further strengthening trilateral relations among South Korea, China and Japan would be highly beneficial,' as Northeast Asia sits at the fault line between the North Korea–China–Russia bloc and South Korea–US–Japan cooperation. 'As a group that intersects both triangular frameworks, our cooperation could serve as a bridge for promoting shared prosperity and safety,' Chung, who serves as the founder and incumbent chair of the NEAR Foundation, said in his opening speech during the forum "The Trump 2.0 Era and its Implications on Northeast Asia." "Such efforts could help ease or neutralize tensions and mitigate sources of conflict in the region." Kim Sung-han, a former national security adviser in the previous Yoon Suk Yeol administration, underscored that "the geopolitical confrontation between North Korea–China–Russia alignment and the ROK–US–Japan partnership is likely to intensify further." The ROK stands for the Republic of Korea, the official name of South Korea. Kim elucidated that the US has been doubling down on its strategic pivot to the Indo-Pacific region from Europe, setting the termination of the war in Ukraine in sight, while curtailing its military engagement in the Middle East. At the same time, China is expected to bolster its strategic partnership with Russia while reinvigorating ties with North Korea. 'In this context, trilateral cooperation among ROK, China and Japan becomes increasingly important to help ease regional tensions and prevent further polarization,' commented Kim, who currently serves as a professor of the Graduate School of International Studies at Korea University. Kim further explained, 'Trump 2.0's foreign policy is likely to push the Northeast Asian order toward a binary confrontation, which could weaken the strategic foundation for trilateral cooperation among ROK, China and Japan." 'Paradoxically, however, in the face of rising tensions, pragmatic and interest-based cooperation among those three countries may become even more necessary,' Kim said. 'As a result, Korea-China-Japan trilateral cooperation could serve as a 'diplomatic shock absorber' that helps ease geopolitical tensions and maintain regional equilibrium.' In his keynote address, Yun Byung-se, former foreign minister under the Park Geun-hye administration, said, 'Dialogue, exchanges and cooperation among South Korea, China and Japan are extremely valuable assets, amid the seismic geopolitical and geoeconomic shifts.' Observers also concurred that the North Korean nuclear challenge underscored the need for tighter Korea-China-Japan cooperation. Yun pointed out that 'North Korea will negotiate from its most advantageous strategic position since the Korean War' if a summit between Trump and North Korean leader Kim Jong-un materializes. 'Depending on the result, another shock may come to the landscape of Northeast Asia,' Yun said. 'Prior coordination between South Korea and the US, and among South Korea, the US and Japan, as well as close consultation with China, will be necessary.' Voicing similar views, Hitoshi Tanaka, former deputy foreign minister in Japan, also underscored that 'especially on pressing issues such as North Korea's nuclear program, close trilateral coordination is imperative.' Observers said this year's Asia-Pacific Economic Cooperation summit — set for late October to early November in Gyeongju, North Gyeongsang Province — will provide a valuable venue to advance trilateral cooperation. 'We understand China's sensitivity regarding Taiwan,' Tanaka said. 'However, just as APEC clearly separates political and security matters, including Taiwan in such frameworks should be considered to demonstrate that economic cooperation can transcend political divides.' The APEC summit will invite leaders from 21 countries in the Indo-Pacific region, including South Korea, the US, China, Japan and Taiwan. 'We hope that the leaders of our three countries — South Korea, China and Japan — will also take advantage of this opportunity to engage in meaningful dialogue,' Chung of the NEAR Foundation said. 'Regardless of the challenges that may arise, South Korea, China and Japan should aim to be in the same boat and remain committed to discussing any issue in depth. In this regard, we must not make the mistake of allowing the past to hinder the future,' Chung added.


Korea Herald
4 hours ago
- Korea Herald
Korean biopharma firms gear up for record presence at BIO USA 2025
Samsung Biologics to showcase CDMO scale-up, digital transformation with largest Korean booth Korean pharmaceutical and biotechnology companies are gearing up for a strong presence at the 2025 BIO International Convention (BIO USA), one of the world's largest biopharma exhibitions, which will take place in Boston starting June 16. Organized annually by the Biotechnology Innovation Organization, BIO USA rotates among major US biotech hubs and serves as a premier global platform for industry leaders to explore strategic partnerships and collaborations. This year's convention, held under the theme 'The World Can't Wait,' will run from June 16 to 19 at the Boston Convention & Exhibition Center. The event is expected to draw more than 9,000 companies from 88 countries and over 20,000 professionals from across the biopharma sector. Roughly 80 Korean companies and organizations will participate by setting up booths. Samsung Biologics Samsung Biologics, one of the largest exhibitors, will mark its 13th consecutive year taking part in the event. It will set up a 167-square-meter booth at the entrance of the exhibition hall — the area with the highest foot traffic — to maximize visibility and draw visitor attention. The booth will showcase the company's expanding contract development and manufacturing organization capabilities through high-tech features such as an LED display wall and interactive touchscreens. These elements are designed to communicate Samsung's advanced service offerings with a strong emphasis on digital transformation in biopharma. Highlights will include a comprehensive look at Samsung Biologics' latest advancements, such as the recent launch of its fifth manufacturing plant, boosting its total production capacity to 784,000 liters — among the highest in the world. The company will also spotlight its capabilities in multi-specific antibody development, its newly introduced antibody-drug conjugate services and AI-driven operational systems, all of which support its goal of becoming a global top-tier CDMO. Other leading Korean CDMO and CMO firms — Celltrion, SK Biopharmaceuticals and Lotte Biologics — will also be attending, competing for new contracts against major players from the US, China and Japan. Celltrion, participating for the 16th year, will operate its own booth to promote products and engage with potential partners, while SK Biopharmaceuticals plans to focus on increasing global brand recognition through a series of high-level business development meetings. Lotte Biologics will showcase its ADC production facilities at the Syracuse Bio Campus and unveil the development roadmap for its Songdo Bio Campus Plant 1, scheduled to begin commercial operations in 2027. Although Daewoong Pharmaceutical and Hanmi Pharmaceutical will not operate a booth at the event, they will participate through business meetings, aiming to strengthen their global presence by showcasing ongoing research and development efforts in new drug discovery. The Cha Vaccine Institute will use the event to promote its shingles (CVI-VZV-001) and hepatitis B (CVI-HBV-002) vaccines, focusing on licensing and joint development opportunities. The institute aims to build partnerships across Southeast Asia, the Middle East, Europe and Latin America to explore co-development and tech transfer prospects. The Cha Vaccine Institute will also participate in the company presentation sessions and the Korea Pavilion pitching event, where it will outline its research pipelines and market strategies. 'We will introduce our proprietary adjuvant platform and vaccine development capabilities at BIO USA, aiming to turn this exposure into real business outcomes,' said Yeom Jeong-seon, CEO of the Cha Vaccine Institute. Meanwhile, Korea BIO will play a significant role at the convention. The Korea Pavilion will feature a record 51 Korean companies, and Korea BIO will facilitate discussions with the US BIO association on key issues, including customs regulations, drug pricing and supply chain resilience, while also providing a partnering platform for domestic companies. According to an industry insider, Korea stands to benefit significantly from shifting global dynamics at this year's BIO USA. 'As US-China tensions reshape the global biotech supply chain, Korean firms that can quickly adapt to geopolitical shifts are well-positioned to secure major deals. Their strong technological base and aggressive manufacturing scale-up efforts make them attractive alternatives to Chinese firms facing regulatory hurdles, potentially positioning Korea as a central beneficiary in the new global order,' the official said, on condition of anonymity.